NR4A1 and breast carcinoma: The combined SOFT-TEXT trials demonstrated that the addition of ovarian suppression to tamoxifen or an aromatase inhibitor significantly reduces distant (recurrence-)free survival in premenopausal women with hormone receptor-positive, HER2-negative breast cancer with a high risk of recurrence, when compared to tamoxifen alone [6,7].